Quest Diagnostics Inc vs Hormel Foods Corp — how do they compare? Quest Diagnostics Inc trades at $230.76 (market cap $25.48B), while Hormel Foods Corp trades at $19.17 (market cap $10.69B). The key difference: Quest Diagnostics Inc is far larger — about 2.4× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Hormel Foods Corp for 99 Days on average.
| DGX | HRL | |
|---|---|---|
Market Cap | $25.48B | $10.69B |
Volume | 941,866 | 10,041,387 |
Sector | Health | Consumer Staples |
52-Week High | $247.45 | $26.50 |
52-Week Low | $173.49 | $19.42 |
Typical Hold Time | 56 Days | 99 Days |
Enterprise Value | $31.23B | $12.67B |
Dividend Yield | 1.49% | 6.02% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Hormel Foods (HRL) trades at $19.23, down 1.64% on the day, with a bearish technical outlook despite recent earnings beats. The company maintains a P/E of 31.32 and P/S of 0.88, with net income margin at 2.82%. Recent $1.06B Brakebush acquisition aims to expand foodservice presence, while dividend consistency remains a key investor focus with 60 consecutive years of increases.
Outlook remains cautious with mixed analyst sentiment (20% buy, 57% hold) and a $24.25 consensus target offering 26% upside. Risks include margin pressure, acquisition integration challenges, and declining dividend growth rates. The stock presents value potential but requires monitoring of operational execution amid competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →